Colorectal Cancer

Chris4Life Colon Cancer Foundation and Myriad Genetics have announced an educational campaign to help individuals learn more about the history of cancer in their family, which may aid them in the prevention or treatment of future cancers.

Our cancer story began on a perfect August night.

Patients with heavily pretreated colorectal cancer who harbored genetic defects in DNA mismatch repair (MMR) experienced high response rates when treated with the PD-1 inhibitor Keytruda (pembrolizumab) in a recent study.

After receiving approvals for advanced gastric cancer and metastatic non–small cell lung cancer in 2014, Cyramza (ramucirumab) gained yet another approval in April 2015.

The FDA has approved second-line Cyramza in combination with FOLFIRI chemotherapy regimen as a treatment for patients with metastatic colorectal cancer following progression on a first-line Avastin-containing regimen.

A recent study joins a body of evidence suggesting that long-term, regular aspirin use is associated with a reduced risk for cancer, with the most dramatic reduction being seen in colorectal cancer incidence.

ON THE VERGE OF UNDERSTANDING: That's what the cover of this issue of CURE declares, and that's exactly where science is when it comes to figuring out colorectal cancer today.

Caring for a loved one means being there through treatment, side effects and worry—but also finding time for yourself.

The diagnosis of a hereditary syndrome that can lead to colorectal cancer—such as Lynch syndrome or familial adenomatous polyposis (FAP)—can be permanently life-changing, counselors and patients agree.

The incidence of colorectal cancer has been steadily rising by about 1.5 percent per year for people under 50.

Advances in the treatment of metastatic colorectal cancer have tripled survival rates, but more profound leaps are anticipated as researchers unravel the disease's complexities.

After treatment for stage 4 colorectal cancer, a country singer is using his talents to express his gratitude and help others.

For survivors of colorectal cancer, struggles can include negative body image, persistent gastrointestinal problems and sexual dysfunction—issues that can diminish quality of life and jeopardize relationships.

Hereditary syndromes that can cause colorectal cancers are uncommon, but for those who have them, diagnosis and preventive measures are key.

Screening has improved the prevention and early detection of colorectal cancer, but how can it reach more people?

March is Colorectal Cancer Awareness month and I'm happy to be part of the sea of blue that is preventing others from enduring a diagnosis of colon cancer.

Following cancer treatment, I wanted to regain some strength and stamina. Where would I start?

Genetic testing is a fascinating and provocative aspect of medicine today as it has implications for our some of our most pronounced human experiences: life, death, reproduction, parenthood, familial bonds, and one's mortality.

Howard S. Hochster, an oncologist at Yale Cancer Center who specializes in gastrointestinal cancers, explains when and why individuals should consider colorectal cancer screening.

A potential biomarker called NRP-1 may indicate longer progression-free survival with tivozanib over Avastin for patients with metastatic colorectal cancer.

I realized I couldn't be the only person so devastated by the effects and aftermath of cancer treatment. I decided to become a yoga teacher to help other patients and survivors.

Patients with newly diagnosed metastatic colorectal cancer who had higher levels of vitamin D in their blood lived a median eight months longer and experienced greater disease-free survival after their cancer treatment.

One of the greatest challenges facing potential Lynch syndrome carriers is not having advice on the implications of a pending test and a subsequent positive result.

This Valentine's Day is extra special as our hearts are brimmed with happiness and our lives are filled with love. I recognize the courage and beauty it takes to live with cancer together.

My goal is to educate doctors around the globe about helping to diagnose Lynch syndrome and to continue to help patients who need support.

Phase 2 Chinese study shows famitinib, a multi-targeted tyrosine kinase inhibitor, led to a small improvement in progression-free survival in patients with advanced, previously treated metastatic colorectal cancer.

Last week, I walked the massive halls of Moscone West in San Francisco and attended the Gastrointestinal Cancers Symposium, better known as ASCO GI. It is a meeting I always feel quite privileged to attend; it offers a glimpse into the work, passion, and expertise that goes into the many aspects of being able to live with metastatic colon cancer.

The Food and Drug Administration's calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.

Patients with metastatic colorectal cancer treated with Cyramza and standard FOLFIRI lived a median of 1.6 months longer than patients treated with FOLFIRI alone, according to results from the phase 3 RAISE trial.

Intensifying the chemotherapy component of a standard regimen containing Avastin reduced the risk of death and increased five-year overall survival in newly diagnosed metastatic colorectal cancer.